Emerging Drug Developer: Tolerx
Emerging Drug Developer: Tolerx
Holding promising Phase II data for a monoclonal antibody lined up for a late-stage race to the FDA, Tolerx found itself in the sweet spot of biotech deal making. And GlaxoSmithKline was just one of a number of companies to make a bid for it. For Tolerx CEO Douglas Ringler, the $760 million deal they struck gives the company enough cash to make it all the way through to a BLA. But there's little time for relaxation. Tolerx is engaged in a competitive race to get its CD3 program all the way to the FDA. And it plans to be first. Article
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
